Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma

Case report

Satoshi Takahashi, Yuichi Hirose, Eiji Ikeda, Raita Fukaya, Takeshi Kawase

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The authors describe the case of a patient with a glioblastoma multiforme who showed remarkably good response to chemotherapy. A genetic analysis using comparative genomic hybridization (CGH) revealed that the tumor had a gain on the q arm of chromosome 1 (1q). Using CGH for a series of genetic analyses of more than 180 patients with gliomas, six were found to have a demonstrated 1q gain. Although the tumors in all six of these cases were histopathologically diagnosed as high-grade gliomas, compared with other malignant gliomas they demonstrated a good prognosis because of their favorable chemotherapeutic sensitivity. In immunohistochemical tests, most of the tumor cells in these cases were negative for O6-methylguanine-DNA methyltransferase, which antagonizes the effect of DNA-alkylating chemotherapeutic agents. The authors believed that a gain of 1q could be produced through the genetic events that cause loss of 1p, because these chromosomal aberrations have an imbalance of DNA copy number in common (1p < 1q). A gain of 1q is an infrequent chromosomal aberration and its clinical importance should be investigated in a larger study; however, patients with malignant gliomas demonstrating a 1q gain possibly show longer survival and good response to chemotherapy similar to patients with tumors demonstrating 1p loss. The importance of using genetic analysis for gliomas is emphasized in this report because it may help in selecting cases responsive to chemotherapy and because appropriate treatment for these patients will lead to progress in the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalJournal of Neurosurgery
Volume106
Issue number3
DOIs
Publication statusPublished - 2007 Mar

Fingerprint

Glioma
Chromosomes
Drug Therapy
Comparative Genomic Hybridization
Chromosome Aberrations
DNA
Neoplasms
Chromosomes, Human, Pair 1
Alkylating Agents
Methyltransferases
Glioblastoma
Survival
Therapeutics

Keywords

  • Chemotherapy
  • Chromosome arm 1q
  • Comparative genomic hybridization
  • Glioblastoma multiforme

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma : Case report. / Takahashi, Satoshi; Hirose, Yuichi; Ikeda, Eiji; Fukaya, Raita; Kawase, Takeshi.

In: Journal of Neurosurgery, Vol. 106, No. 3, 03.2007, p. 488-494.

Research output: Contribution to journalArticle

Takahashi, Satoshi ; Hirose, Yuichi ; Ikeda, Eiji ; Fukaya, Raita ; Kawase, Takeshi. / Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma : Case report. In: Journal of Neurosurgery. 2007 ; Vol. 106, No. 3. pp. 488-494.
@article{08f29dceb4b94cd8af4e8a5db4de8200,
title = "Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma: Case report",
abstract = "The authors describe the case of a patient with a glioblastoma multiforme who showed remarkably good response to chemotherapy. A genetic analysis using comparative genomic hybridization (CGH) revealed that the tumor had a gain on the q arm of chromosome 1 (1q). Using CGH for a series of genetic analyses of more than 180 patients with gliomas, six were found to have a demonstrated 1q gain. Although the tumors in all six of these cases were histopathologically diagnosed as high-grade gliomas, compared with other malignant gliomas they demonstrated a good prognosis because of their favorable chemotherapeutic sensitivity. In immunohistochemical tests, most of the tumor cells in these cases were negative for O6-methylguanine-DNA methyltransferase, which antagonizes the effect of DNA-alkylating chemotherapeutic agents. The authors believed that a gain of 1q could be produced through the genetic events that cause loss of 1p, because these chromosomal aberrations have an imbalance of DNA copy number in common (1p < 1q). A gain of 1q is an infrequent chromosomal aberration and its clinical importance should be investigated in a larger study; however, patients with malignant gliomas demonstrating a 1q gain possibly show longer survival and good response to chemotherapy similar to patients with tumors demonstrating 1p loss. The importance of using genetic analysis for gliomas is emphasized in this report because it may help in selecting cases responsive to chemotherapy and because appropriate treatment for these patients will lead to progress in the treatment of malignant gliomas.",
keywords = "Chemotherapy, Chromosome arm 1q, Comparative genomic hybridization, Glioblastoma multiforme",
author = "Satoshi Takahashi and Yuichi Hirose and Eiji Ikeda and Raita Fukaya and Takeshi Kawase",
year = "2007",
month = "3",
doi = "10.3171/jns.2007.106.3.488",
language = "English",
volume = "106",
pages = "488--494",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma

T2 - Case report

AU - Takahashi, Satoshi

AU - Hirose, Yuichi

AU - Ikeda, Eiji

AU - Fukaya, Raita

AU - Kawase, Takeshi

PY - 2007/3

Y1 - 2007/3

N2 - The authors describe the case of a patient with a glioblastoma multiforme who showed remarkably good response to chemotherapy. A genetic analysis using comparative genomic hybridization (CGH) revealed that the tumor had a gain on the q arm of chromosome 1 (1q). Using CGH for a series of genetic analyses of more than 180 patients with gliomas, six were found to have a demonstrated 1q gain. Although the tumors in all six of these cases were histopathologically diagnosed as high-grade gliomas, compared with other malignant gliomas they demonstrated a good prognosis because of their favorable chemotherapeutic sensitivity. In immunohistochemical tests, most of the tumor cells in these cases were negative for O6-methylguanine-DNA methyltransferase, which antagonizes the effect of DNA-alkylating chemotherapeutic agents. The authors believed that a gain of 1q could be produced through the genetic events that cause loss of 1p, because these chromosomal aberrations have an imbalance of DNA copy number in common (1p < 1q). A gain of 1q is an infrequent chromosomal aberration and its clinical importance should be investigated in a larger study; however, patients with malignant gliomas demonstrating a 1q gain possibly show longer survival and good response to chemotherapy similar to patients with tumors demonstrating 1p loss. The importance of using genetic analysis for gliomas is emphasized in this report because it may help in selecting cases responsive to chemotherapy and because appropriate treatment for these patients will lead to progress in the treatment of malignant gliomas.

AB - The authors describe the case of a patient with a glioblastoma multiforme who showed remarkably good response to chemotherapy. A genetic analysis using comparative genomic hybridization (CGH) revealed that the tumor had a gain on the q arm of chromosome 1 (1q). Using CGH for a series of genetic analyses of more than 180 patients with gliomas, six were found to have a demonstrated 1q gain. Although the tumors in all six of these cases were histopathologically diagnosed as high-grade gliomas, compared with other malignant gliomas they demonstrated a good prognosis because of their favorable chemotherapeutic sensitivity. In immunohistochemical tests, most of the tumor cells in these cases were negative for O6-methylguanine-DNA methyltransferase, which antagonizes the effect of DNA-alkylating chemotherapeutic agents. The authors believed that a gain of 1q could be produced through the genetic events that cause loss of 1p, because these chromosomal aberrations have an imbalance of DNA copy number in common (1p < 1q). A gain of 1q is an infrequent chromosomal aberration and its clinical importance should be investigated in a larger study; however, patients with malignant gliomas demonstrating a 1q gain possibly show longer survival and good response to chemotherapy similar to patients with tumors demonstrating 1p loss. The importance of using genetic analysis for gliomas is emphasized in this report because it may help in selecting cases responsive to chemotherapy and because appropriate treatment for these patients will lead to progress in the treatment of malignant gliomas.

KW - Chemotherapy

KW - Chromosome arm 1q

KW - Comparative genomic hybridization

KW - Glioblastoma multiforme

UR - http://www.scopus.com/inward/record.url?scp=33847614415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847614415&partnerID=8YFLogxK

U2 - 10.3171/jns.2007.106.3.488

DO - 10.3171/jns.2007.106.3.488

M3 - Article

VL - 106

SP - 488

EP - 494

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 3

ER -